Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Acta Paediatr. 2022 Feb;111(2):215-224. doi: 10.1111/apa.15948. Epub 2021 Jun 4.
Growth hormone treatment was introduced in the 1950s to address growth disturbances and metabolic abnormalities. Hundreds of thousands of children have been treated, with gradual expansion of treatment indications. From initially being offered only to patients with severe growth hormone deficiency, today many children are treated for conditions in which the associated short stature is not primarily thought to be due to deficient endogenous growth hormone secretion. This review discusses the history, physiology and safety of growth hormone treatment, with focus on the long-term risks of mortality, cardiovascular morbidity and cancer. Conclusion: Continuous follow-up is needed to increase our knowledge of the long-term treatment safety.
生长激素治疗始于 20 世纪 50 年代，旨在解决生长障碍和代谢异常问题。已有数十万名儿童接受了治疗，治疗适应症也逐渐扩大。最初仅向严重生长激素缺乏症患者提供治疗，而如今许多儿童因非生长激素缺乏导致的身材矮小接受治疗。本文讨论了生长激素治疗的历史、生理学和安全性，重点关注死亡率、心血管发病率和癌症的长期风险。结论：需要持续随访以增加对长期治疗安全性的认识。
